These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

667 related items for PubMed ID: 26289956

  • 41. Simultaneous vaccination of Chinese applicants for a United States immigrant visa.
    Hua L, Hongtao H, Shunqin W, Jinping G, Jiandong C, Zhaoliang L, Xinwen F.
    Travel Med Infect Dis; 2008 May; 6(3):130-6. PubMed ID: 18486068
    [Abstract] [Full Text] [Related]

  • 42. Surveillance of adverse events after the first trivalent inactivated influenza vaccine produced in mammalian cell culture (Flucelvax(®)) reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013-2015.
    Moro PL, Winiecki S, Lewis P, Shimabukuro TT, Cano M.
    Vaccine; 2015 Nov 27; 33(48):6684-8. PubMed ID: 26518405
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. An open-label, randomized, multi-center study of the immunogenicity and safety of DTaP-IPV (Kinrix™) co-administered with MMR vaccine with or without varicella vaccine in healthy pre-school age children.
    Klein NP, Weston WM, Kuriyakose S, Kolhe D, Howe B, Friedland LR, Van Der Meeren O.
    Vaccine; 2012 Jan 11; 30(3):668-74. PubMed ID: 22064267
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Safety review of tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccines (Tdap) in adults aged ≥65 years, Vaccine Adverse Event reporting System (VAERS), United States, September 2010-December 2018.
    Haber P, Moro PL, Ng C, Dores GM, Perez-Vilar S, Marquez PL, Cano M.
    Vaccine; 2020 Feb 05; 38(6):1476-1480. PubMed ID: 31883809
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Hypotonic-hyporesponsive episodes reported to the Vaccine Adverse Event Reporting System (VAERS), 1996-1998.
    DuVernoy TS, Braun MM.
    Pediatrics; 2000 Oct 05; 106(4):E52. PubMed ID: 11015547
    [Abstract] [Full Text] [Related]

  • 50. Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip) to adults aged ≥60 years: an open-label, randomised trial.
    Zimmermann U, Gavazzi G, Richard P, Eymin C, Soubeyrand B, Baudin M.
    Vaccine; 2013 Mar 01; 31(11):1496-502. PubMed ID: 23313654
    [Abstract] [Full Text] [Related]

  • 51. Eradicating polio: how the world's pediatricians can help stop this crippling illness forever.
    Orenstein WA, Committee on Infectious Diseases.
    Pediatrics; 2015 Jan 01; 135(1):196-202. PubMed ID: 25548328
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial.
    Snider CJ, Zaman K, Estivariz CF, Yunus M, Weldon WC, Wannemuehler KA, Oberste MS, Pallansch MA, Wassilak SG, Bari TIA, Anand A.
    Lancet; 2019 Jun 29; 393(10191):2624-2634. PubMed ID: 31104832
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Immunogenicity and safety of one dose of diphtheria, tetanus, acellular pertussis and poliomyelitis vaccine (Repevax®) followed by two doses of diphtheria, tetanus and poliomyelitis vaccine (Revaxis®) in adults aged ≥ 40 years not receiving a diphtheria- and tetanus-containing vaccination in the last 20 years.
    Dominicus R, Galtier F, Richard P, Baudin M.
    Vaccine; 2014 Jun 30; 32(31):3942-9. PubMed ID: 24852717
    [Abstract] [Full Text] [Related]

  • 56. [Safety surveillance in the National Vaccination Programme; fewer adverse events with the DTP-IPV-Hib vaccine after the transition to an acellular pertussis component in 2005].
    van der Maas NA, David S, Kemmeren JM, Vermeer-de Bondt PE.
    Ned Tijdschr Geneeskd; 2007 Dec 08; 151(49):2732-7. PubMed ID: 18225797
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015.
    Haber P, Moro PL, Lewis P, Woo EJ, Jankosky C, Cano M.
    Vaccine; 2016 May 11; 34(22):2507-12. PubMed ID: 27015735
    [Abstract] [Full Text] [Related]

  • 60. Post-licensure surveillance of trivalent adjuvanted influenza vaccine (aIIV3; Fluad), Vaccine Adverse Event Reporting System (VAERS), United States, July 2016-June 2018.
    Haber P, Moro PL, Ng C, Dores GM, Lewis P, Cano M.
    Vaccine; 2019 Mar 07; 37(11):1516-1520. PubMed ID: 30739795
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.